Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Hernandez, Santiagoa | McClendon, McKee J.b | Zhou, Xiao-Hua Andrewc; d | Sachs, Michaeld | Lerner, Alan J.b; e; f; *
Affiliations: [a] Case Western Reserve University, School of Medicine, Cleveland, OH, USA | [b] University Memory and Cognition Center, Case Western Reserve University, Cleveland, OH, USA | [c] Department of Biostatistics School of Public Health and Community Medicine, Department of Psychiatry and Behavior Sciences School of Medicine University of Washington, Seattle, WA, USA | [d] HSR&D Center of Excellence, U.S. Department of Veterans Affairs, Puget Sound Health Care System, Seattle, WA, USA | [e] Department of Neurology, Case Western Reserve University, Cleveland, OH, USA | [f] University Hospitals, Case Medical Center, Cleveland, OH, USA
Correspondence: [*] Corresponding author: Alan J. Lerner, MD, Memory and Cognition Center, 3619 Park East Drive #211, Beachwood, OH 44122, USA. Tel.: +1 216 464 6412; Fax: +1 216 464 6403; E-mail: [email protected].
Abstract: Existing research shows differences in medication use for Alzheimer's disease (AD) based on demographics such as race, ethnicity, and geographical location. To determine individual and community characteristics associated with differences in acetylcholinesterase inhibitor (AChEI) and memantine use in AD, 3,049 AD subjects were drawn from 30 centers and evaluated using the Uniform data set (UDS). Cases were evaluated at the individual level within the context of 31 communities (one center encompassed two separate geographical regions). Multivariate analysis was used to determine the significance of individual variables on medication use. Compared to non-Hispanic Whites, Blacks were less likely to use AChEI and memantine with odds ratios (OR) of 0.59 (95% CI 0.46–0.76) and 0.43 (95% CI 0.32–0.57), respectively. Compared to non-Hispanic Whites, non-Black Hispanics were less likely to use memantine (OR = 0.69 (95% CI 0.49–0.98)). No association was found between the proportion of Blacks or non-Black Hispanics versus non-Hispanic Whites at an Alzheimer Disease Center and individual use of AChEI or memantine. Other significant variables include gender, age, marital status, dementia severity, source of referral, AChEI use, and education. Education and age somewhat mitigated disparity. Significant racial and ethnic differences in AChEI and memantine use exist at the individual level regardless of the racial and ethnic composition of the individual's community. Research and initiatives at the societal level may be an important consideration toward addressing these differences.
Keywords: Acetylcholinesterase inhibitor, Alzheimer's disease, disparity, ethnicity, memantine, race
DOI: 10.3233/JAD-2010-1269
Journal: Journal of Alzheimer's Disease, vol. 19, no. 2, pp. 665-672, 2010
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]